MammoScreen
Save to shortlistLast reviewed Nov 9, 2026 against the sources listed on this page · How we review
At a glance
MammoScreen by Therapixel is an AI tool for screening mammography and tomosynthesis that marks suspicious findings and gives each exam a cancer suspicion score to support radiologists.
- FDA:
- 510(k) K260714 +4 more
- Epic:
- Not on record
- Named users:
- 2 named in public reports
- Published study:
- Not on record
Description
MammoScreen by Therapixel is an AI tool for screening mammography and tomosynthesis that marks suspicious findings and gives each exam a cancer suspicion score to support radiologists. Its latest version was FDA cleared under K260714 in June 2026.
Quick answers
Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review
- Is MammoScreen FDA cleared?
- The public FDA database has 5 records that our team matched to MammoScreen. The most recent is 510(k) K260714 (MammoScreen® (5)), decided Jun 2026. Check that the cleared use matches how you plan to use it.FDA record K260714
- Which health systems use MammoScreen?
- Linked public reports name 2 organizations: Mayo Clinic and Axia Women's Health. "Who's using this" below lists them all, plus any the maker reports. Ask the vendor for a reference at an organization like yours.Mayo Clinic (PR Newswire) Axia Women's Health (Axia Women's Health)
Security & contracting
The maker has not reported these details yet. Ask the vendor directly during evaluation.
- Workflow stage
- Not reported
- Integrations
- Not reported
- Data inputs
- Not reported
- Deployment
- Not reported
- Signs a BAA
- Not reported
- SOC 2 report
- Not reported
- HITRUST
- Not reported
- Evidence type
- Regulatory submission summary
Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.
Who's using this
2 organizationsOrganizations named in public announcements or by the developer. Inclusion is not an endorsement.
Last checked Nov 9, 2026. Spot an error? Let us know through the discussion below.
Get weekly updates for Oncology
Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.
Sources
This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.
Website FDA RecordFDA database records
- K260714 · 510(k) · Jun 2026MammoScreen® (5)
- K243685 · 510(k) · Aug 2025MammoScreen BD
- K243679 · 510(k) · Jul 2025MammoScreen® (4)
- K241561 · 510(k) · Oct 2024MammoScreen BD
- K240301 · 510(k) · Aug 2024MammoScreen® (3)
Matched by our team from the public FDA database; checked Nov 10, 2026.
History (8)Show
Dated events on this listing's public record, newest first.
- Sep 27, 2026
Added to CIFoundry
- Jun 26, 2026
FDA 510(k) K260714 decision datesource
- Sep 16, 2025
News report names Axia Women's Health as a user (Axia Women's Health)source
- Aug 22, 2025
FDA 510(k) K243685 decision datesource
- Jul 3, 2025
FDA 510(k) K243679 decision datesource
- Apr 23, 2025
News report names Mayo Clinic as a user (PR Newswire)source
- Oct 2, 2024
FDA 510(k) K241561 decision datesource
- Aug 1, 2024
FDA 510(k) K240301 decision datesource
Developer
Therapixel
Evaluating this tool?
Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.
Prepare evaluation packetChecklist for your role: Admin · Physician · IT · Compliance
Compare similar tools →